Emergent BioSolutions Inc. (NYSE:EBS) Short Interest Up 6.6% in June

Emergent BioSolutions Inc. (NYSE:EBS) saw a large increase in short interest in June. As of June 15th, there was short interest totalling 6,330,000 shares, an increase of 6.6% from the May 31st total of 5,940,000 shares. Approximately 12.6% of the shares of the stock are short sold. Based on an average daily volume of 4,550,000 shares, the short-interest ratio is presently 1.4 days.

Wall Street Analyst Weigh In

Separately, Benchmark reaffirmed a “buy” rating and set a $8.00 price objective on shares of Emergent BioSolutions in a report on Tuesday.

Emergent BioSolutions Stock Up 0.7 %

Shares of EBS opened at $7.54 on Thursday. The stock has a market capitalization of $395.11 million, a price-to-earnings ratio of -0.68 and a beta of 1.62. Emergent BioSolutions has a 1 year low of $1.42 and a 1 year high of $8.29. The business’s 50 day simple moving average is $5.31 and its 200-day simple moving average is $3.32. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.08 and a quick ratio of 0.55.

Emergent BioSolutions (NYSE:EBS) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.59 earnings per share for the quarter, beating the consensus estimate of ($3.65) by $4.24. The firm had revenue of $300.40 million for the quarter. Emergent BioSolutions had a negative return on equity of 18.53% and a negative net margin of 47.68%. During the same period in the prior year, the firm posted ($3.17) EPS. As a group, equities analysts expect that Emergent BioSolutions will post -1.98 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Kathryn C. Zoon sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $6.11, for a total value of $61,100.00. Following the transaction, the director now directly owns 54,482 shares of the company’s stock, valued at approximately $332,885.02. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders have sold 12,919 shares of company stock valued at $75,831. Corporate insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Emergent BioSolutions

Several large investors have recently modified their holdings of EBS. CoreCap Advisors LLC bought a new position in shares of Emergent BioSolutions during the 4th quarter valued at approximately $33,000. Avidian Wealth Solutions LLC bought a new position in Emergent BioSolutions in the 1st quarter valued at $33,000. Tidal Investments LLC bought a new position in shares of Emergent BioSolutions during the 1st quarter worth $34,000. Laurion Capital Management LP bought a new position in shares of Emergent BioSolutions during the 3rd quarter worth $37,000. Finally, Tower Research Capital LLC TRC grew its position in shares of Emergent BioSolutions by 52.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 19,867 shares of the biopharmaceutical company’s stock worth $48,000 after buying an additional 6,823 shares in the last quarter. Institutional investors own 78.40% of the company’s stock.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.